364 related articles for article (PubMed ID: 25780974)
41. Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis.
Yamada T; Hiramoto N; Mori T; Yamashita D; Tai Y; Yamamoto R; Nishikubo M; Maruoka H; Sakamoto K; Takeuchi K; Nannya Y; Ogawa S; Ishikawa T
Blood Cancer J; 2023 Aug; 13(1):119. PubMed ID: 37558659
[No Abstract] [Full Text] [Related]
42. A woman with rare blastic plasmacytoid dendritic cell neoplasm on the face.
Huang YY; Liu YR; Li K; Li K; Liu SH
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jan; 121(1):e16-8. PubMed ID: 26159087
[TBL] [Abstract][Full Text] [Related]
43. Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review.
Kim MJ; Nasr A; Kabir B; de Nanassy J; Tang K; Menzies-Toman D; Johnston D; El Demellawy D
J Pediatr Hematol Oncol; 2017 Oct; 39(7):528-537. PubMed ID: 28906324
[TBL] [Abstract][Full Text] [Related]
44. [Blastic plasmocytoid dendritic cell neoplasm: Report of one case].
Tapia E O; Kam C S; Rifo L P; Villaseca H M
Rev Med Chil; 2012 Oct; 140(10):1321-4. PubMed ID: 23559291
[TBL] [Abstract][Full Text] [Related]
45. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm.
He J; Garcia MB; Connors JS; Nuñez CA; Quesada AE; Gibson A; Roth M; Cuglievan B; Pemmaraju N; McCall D
J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1001-e1004. PubMed ID: 37661300
[TBL] [Abstract][Full Text] [Related]
46. Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea.
Kim HS; Kim HJ; Kim SH; Choi JY; Ko YH; Kim WS; Jung CW; Kim SJ
Korean J Intern Med; 2017 Sep; 32(5):890-899. PubMed ID: 28870016
[TBL] [Abstract][Full Text] [Related]
47. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.
Sakamoto K; Katayama R; Asaka R; Sakata S; Baba S; Nakasone H; Koike S; Tsuyama N; Dobashi A; Sasaki M; Ichinohasama R; Takakuwa E; Yamazaki R; Takizawa J; Maeda T; Narita M; Izutsu K; Kanda Y; Ohshima K; Takeuchi K
Leukemia; 2018 Dec; 32(12):2590-2603. PubMed ID: 29795241
[TBL] [Abstract][Full Text] [Related]
48. Blastic plasmacytoid dendritic cell neoplasm: cytopathologic findings.
Zheng G; Schmieg J; Guan H; Ali SZ
Acta Cytol; 2012; 56(2):204-8. PubMed ID: 22378086
[TBL] [Abstract][Full Text] [Related]
49. [Blastic plasmacytoid dendritic cell neoplasm: two case reports].
Kaabar M; Lemaire P; Laribi K; Sandrini J; Pineau-Vincent F
Ann Biol Clin (Paris); 2015; 73(6):733-6. PubMed ID: 26553703
[TBL] [Abstract][Full Text] [Related]
50. Neoplasms derived from plasmacytoid dendritic cells.
Facchetti F; Cigognetti M; Fisogni S; Rossi G; Lonardi S; Vermi W
Mod Pathol; 2016 Feb; 29(2):98-111. PubMed ID: 26743477
[TBL] [Abstract][Full Text] [Related]
51. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.
Frankel AE; Woo JH; Ahn C; Pemmaraju N; Medeiros BC; Carraway HE; Frankfurt O; Forman SJ; Yang XA; Konopleva M; Garnache-Ottou F; Angelot-Delettre F; Brooks C; Szarek M; Rowinsky E
Blood; 2014 Jul; 124(3):385-92. PubMed ID: 24859366
[TBL] [Abstract][Full Text] [Related]
52. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
[TBL] [Abstract][Full Text] [Related]
53. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
Wang S; Wang X; Liu M; Bai O
Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234
[TBL] [Abstract][Full Text] [Related]
54. BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM --A RAPIDLY EVOLVING ENTITY. CASE REPORT.
Andrese E; Solovăstru LG; Dimofte G; Ferariu D; Porumb V; Vâţă D; Iancul LS
Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):379-83. PubMed ID: 26204640
[TBL] [Abstract][Full Text] [Related]
55. Myeloid Cell Nuclear Differentiation Antigen (MNDA) Expression Distinguishes Extramedullary Presentations of Myeloid Leukemia From Blastic Plasmacytoid Dendritic Cell Neoplasm.
Johnson RC; Kim J; Natkunam Y; Sundram U; Freud AG; Gammon B; Cascio MJ
Am J Surg Pathol; 2016 Apr; 40(4):502-9. PubMed ID: 26796502
[TBL] [Abstract][Full Text] [Related]
56. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
Zhang X; Sun J; Yang M; Wang L; Jin J
Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
[TBL] [Abstract][Full Text] [Related]
57. Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q.
Mitteldorf C; Bertsch HP; Baumgart M; Haase D; Wulf G; Schön MP; Rosenwald A; Neumann C; Kaune KM
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1225-9. PubMed ID: 21923812
[TBL] [Abstract][Full Text] [Related]
58. Blastic plasmacytoid dendritic cell neoplasm with cutaneous presentation: A case series in children.
Chan G; Akintorin S; Luu M; Harter N
Pediatr Dermatol; 2021 Jul; 38(4):883-886. PubMed ID: 34156718
[TBL] [Abstract][Full Text] [Related]
59. Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Ashok Kumar P; Ombada M; Pemmasani G; Tambe A; Banki K; Gentile T
J Investig Med High Impact Case Rep; 2022; 10():23247096221127114. PubMed ID: 36341907
[TBL] [Abstract][Full Text] [Related]
60. Disseminated Cutaneous Lesions in a Patient With a Medical History of Myelodysplastic Syndrome.
Yun S; Sokol L; Zhang L
JAMA Oncol; 2018 Sep; 4(9):1281-1282. PubMed ID: 29800978
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
